Hereditary Renal Cancer Panel

Pathogenic variants in multiple genes have been implicated in hereditary renal cancer. Hereditary cancer predisposition is often characterized by early age of onset (typically before 50 years) and multiple, multifocal, and/or similar cancers in a single individual or in a closely related family member(s). Pathogenic variants in the genes analyzed by this panel cause variable phenotypes and cancer risks, including nonrenal cancers.

**DISEASE OVERVIEW**

**Etiology**

Approximately 5% of renal cancers are associated with a hereditary cause.

**Inheritance**

- All genes tested on the Hereditary Renal Cancer Panel are autosomal dominant with the exception of the **SDHD** gene, which is autosomal dominant with paternal parent-of-origin effect.
- Some genes are also associated with autosomal recessive childhood cancer predisposition or other syndromes.
- See table below for additional details.

**TEST DESCRIPTION**

See Genes Tested table for genes included in the panel.

**Clinical Sensitivity**

Variable, dependent on phenotype/condition

**Testing Strategy**

**Contraindications for Ordering**

- Should not be ordered to detect somatic variants associated with malignancy as sensitivity for mosaic variants is low with methodology used for germline assays.
- Individuals with hematological malignancy and/or a previous allogenic bone marrow transplant should not undergo molecular genetic testing on peripheral blood specimen.
  - Testing of cultured fibroblasts is required for accurate interpretation of test results.
- When a relative has a previously identified pathogenic variant, see Familial Mutation, Targeted Sequencing (2001961).

**Limitations**

- A negative result does not exclude a heritable form of cancer.
- Diagnostic errors can occur due to rare sequence variations.
- Interpretation of this test result may be impacted if this individual has had an allogeneic stem cell transplantation.
- The following will not be evaluated:
  - Variants outside the coding regions and intron-exon boundaries of the targeted genes
  - Regulatory region variants and deep intronic variants
  - Breakpoints of large deletions/duplications
  - Deletions/duplications in **SMARCA4** and **WT1**
  - Noncoding transcripts

---

**TESTS TO CONSIDER**

**Hereditary Renal Cancer Panel, Sequencing and Deletion/Duplication 2010214**

Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

**Indication for testing:**

- Recommended test to confirm a diagnosis of a hereditary renal cancer syndrome in individuals with a personal or family history of renal cancer.
- When a relative has a previously identified pathogenic sequence variant, see Familial Mutation, Targeted Sequencing (2001961).

**Familial Mutation, Targeted Sequencing 2001961**

Method: Polymerase Chain Reaction/Sequencing

**Indication for testing:**

- Recommended test if there is a known familial sequence variant previously identified in a family member.
- A copy of the family member’s test result documenting the familial variant is required.

See Related Tests
- The following exons are not sequenced due to technical limitations of the assay:
  - SDHC (NM_001035511) 5
  - SDHD (NM_001276506) 4

- The following may not be detected:
  - Deletions/duplications/insertions of any size by massively parallel sequencing
  - Deletions/duplications less than 1kb in the targeted genes by array
  - Some variants due to technical limitations in the presence of pseudogenes, repetitive, or homologous regions
  - Low-level somatic variants
  - Single exon deletions/duplications in the following exons:
    - BAP1 (NM_004656) 1
    - FH (NM_000143) 1
    - FLCN (NM_144997) 8
    - MSH2 (NM_000251) 1; (NM_001258281) 2
    - MSH6 (NM_000179) 10
    - PTEN (NM_000314) 1; (NM_001304717) 1
    - SDHD (NM_001276506) 4
    - SMARCB1 (NM_003073) 5
    - TP53 (NM_001126113) 10; (NM_001126114) 10
    - TSC2 (NM_000548) 17, 29, 41
    - VHL (NM_000551) 1

Analytical Sensitivity

For massively parallel sequencing:

<table>
<thead>
<tr>
<th>Variant Class</th>
<th>Analytical Sensitivity (PPA) Estimatea (%)</th>
<th>Analytical Sensitivity (PPA) 95% Credibility Regiona (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNVs</td>
<td>99.2</td>
<td>96.9-99.4</td>
</tr>
<tr>
<td>Deletions 1-10 bp</td>
<td>93.8</td>
<td>84.3-98.2</td>
</tr>
<tr>
<td>Deletions 11-44 bp</td>
<td>100</td>
<td>87.8-100</td>
</tr>
<tr>
<td>Insertions 1-10 bp</td>
<td>94.8</td>
<td>86.8-98.5</td>
</tr>
<tr>
<td>Insertions 11-23 bp</td>
<td>100</td>
<td>62.1-100</td>
</tr>
</tbody>
</table>

aGenes included on this test are a subset of a larger methods-based validation from which the PPA values are derived.
bp, base pairs; PPA, positive percent agreement; SNVs, single nucleotide variants

Genes Tested

<table>
<thead>
<tr>
<th>Gene</th>
<th>MIM Number</th>
<th>Disorder/Associated Cancer(s)/Tumor(s)</th>
<th>Inheritance</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAP1</td>
<td>603089</td>
<td>BAP1 tumor predisposition syndrome (BAP1-TPDS)</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Associated cancer(s)/tumor(s): uveal melanoma, malignant mesothelioma, cutaneous melanoma, renal cell carcinoma, basal cell carcinoma</td>
<td></td>
</tr>
<tr>
<td>DICER1</td>
<td>606241</td>
<td>DICER1-related disorders</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Associated cancer(s)/tumor(s): pleuropulmonary blastoma, ovarian sex cord-stromal tumors, cystic nephroma, thyroid</td>
<td></td>
</tr>
<tr>
<td>FH</td>
<td>136850</td>
<td>Hereditary leiomyomatosis and renal cell cancer (HLRCC)</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Associated cancer(s)/tumor(s): papillary type 2 renal cancer, cutaneous and uterine leiomyomata</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fumarase Deficiency</td>
<td></td>
</tr>
<tr>
<td>FLCN</td>
<td>607273</td>
<td>Birt-Hogg-Dube syndrome (BHDS)</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Associated cancer(s)/tumor(s): renal</td>
<td></td>
</tr>
<tr>
<td>MET</td>
<td>164860</td>
<td>Hereditary papillary renal cell carcinoma (HPRCC)</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Associated cancer(s)/tumor(s): papillary type 1 renal cancer</td>
<td></td>
</tr>
<tr>
<td>MLH1</td>
<td>120436</td>
<td>Lynch syndrome/hereditary nonpolyposis colorectal cancer (HNPPCC)</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Associated cancer(s)/tumor(s): colorectal, endometrial, stomach, ovarian, and others</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Constitutional mismatch repair deficiency (CMMRD)</td>
<td>AR</td>
</tr>
<tr>
<td>Gene</td>
<td>MIM Number</td>
<td>Disorder/Associated Cancer(s)/Tumor(s)</td>
<td>Inheritance</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>------------------------------------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| MSH2   | 609309     | Lynch syndrome/hereditary nonpolyposis colorectal cancer (HNPCC)  
              Associated cancer(s)/tumor(s): colorectal, endometrial, stomach, ovarian, and others | AD          |
|        |            | Constitutional mismatch repair deficiency (CMMRD)                                                   | AR          |
| MSH6   | 600678     | Lynch syndrome/hereditary nonpolyposis colorectal cancer (HNPCC)  
              Associated cancer(s)/tumor(s): colorectal, endometrial, stomach, ovarian, and others | AD          |
|        |            | Constitutional mismatch repair deficiency (CMMRD)                                                   | AR          |
| PMS2   | 600259     | Lynch syndrome/hereditary nonpolyposis colorectal cancer (HNPCC)  
              Associated cancer(s)/tumor(s): colorectal, endometrial, stomach, ovarian, and others | AD          |
|        |            | Constitutional mismatch repair deficiency (CMMRD)                                                   | AR          |
| PTEN   | 601728     | Cowden syndrome/PTEN hamartoma tumor syndrome  
              Associated cancer(s)/tumor(s): breast, endometrial, thyroid, colon, renal cell carcinoma | AD          |
| SDHB   | 185470     | Associated cancer(s)/tumor(s): paraganglioma, pheochromocytoma, GIST, pulmonary chondroma, renal clear cell carcinoma | AD          |
| SDHC   | 602413     | Associated cancer(s)/tumor(s): paraganglioma, pheochromocytoma, GIST, pulmonary chondroma, renal clear cell carcinoma | AD          |
| SDHD   | 602690     | Associated cancer(s)/tumor(s): paraganglioma, pheochromocytoma, GIST, pulmonary chondroma, renal clear cell carcinoma | AD          |
| SMARCA4| 603254     | Rhabdoid tumor predisposition syndrome  
              Associated cancer(s)/tumor(s): rhabdoid tumor                                                  | AD          |
| SMARCB1| 601607     | Rhabdoid tumor predisposition syndrome  
              Associated cancer(s)/tumor(s): rhabdoid tumor                                                  | AD          |
| TP53   | 191170     | Li-Fraumeni syndrome (LFS)  
              Associated cancer(s)/tumor(s): soft tissue sarcoma, osteosarcoma, central nervous system (CNS) tumor, breast, adrenocortical carcinoma, choroid plexus carcinoma, rhabdomyosarcoma | AD          |
| TSC1   | 605284     | Tuberous sclerosis complex (TSC)  
              Associated cancer(s)/tumor(s): cardiac rhabdomyoma, retinal and other hamartomas, renal angiomyolipoma, subependymal giant cell astrocytoma (SEGA), fibromas | AD          |
| TSC2   | 191092     | Tuberous sclerosis complex (TSC)  
              Associated cancer(s)/tumor(s): cardiac rhabdomyoma, retinal and other hamartomas, renal angiomyolipoma, subependymal giant cell astrocytoma (SEGA), fibromas | AD          |
| VHL    | 608537     | Von Hippel-Lindau (VHL) syndrome  
              Associated cancer(s)/tumor(s): hemangioblastoma, retinal angioma, renal cell carcinoma, pheochromocytoma, neuroendocrine sac tumors, epididymal and broad ligament cystadenomas | AD          |
| WT1    | 607102     | WT1-telated Wilms tumor; WAGR syndrome; Denys-Drash syndrome (DDS); Frasier syndrome  
              Associated cancer(s)/tumor(s): Wilms tumor                                                  | AD          |

*Paternal parent-of-origin effect
AD, autosomal dominant; AR, autosomal recessive

REFERENCES

